Skip to main
NBP

NovaBridge Biosciences (NBP) Stock Forecast & Price Target

NovaBridge Biosciences (NBP) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

NovaBridge Biosciences is experiencing significant growth in research and development, with expenses rising from $41.1 million in FY24 to $62.9 million, reflecting increased investment in its pipeline of clinical programs. The potential for givastomig, a bispecific antibody aimed at treating gastric cancer and other malignancies, shows promise with improved gastrointestinal tolerability compared to competing therapies, positioning the product for substantial market share and translating into a multi-billion-dollar opportunity in the anti-VEGF market. Furthermore, FDA support for accelerated pathways enhances regulatory confidence and reduces timelines for market entry, with an upcoming registrational study set for as early as late 2026, contributing to a more favorable outlook for the company's stock.

Bears say

NovaBridge Biosciences is facing fundamental challenges in its operations, contributing to a negative outlook on its stock. The company reported a significant net loss from continuing operations of $88.3 million for FY2025, which was an increase from $49.7 million in FY2024, alongside an attributable loss per share that showed little improvement. Additionally, high rates of non-utilization of their therapies, despite expected biomarker positivity, coupled with complications in administration for candidates like zolbetuximab, indicate significant hurdles in market adoption and financial stability.

NovaBridge Biosciences (NBP) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of NovaBridge Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About NovaBridge Biosciences (NBP) Forecast

Analysts have given NovaBridge Biosciences (NBP) a Strong Buy based on their latest research and market trends.

According to 1 analysts, NovaBridge Biosciences (NBP) has a Strong Buy consensus rating as of Apr 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

NovaBridge Biosciences (NBP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.